NEW YORK, Jan. 12, 2025 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) and…
Month: January 2025
NEW YORK, Jan. 12, 2025 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) and…
NEW YORK, Jan. 12, 2025 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Capri Holdings Limited (“Capri” or “the Company”) (NYSE: CPRI) and certain of its…
NEW YORK, Jan. 12, 2025 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Capri Holdings Limited (“Capri” or “the Company”) (NYSE: CPRI) and certain of its…
NEW YORK, Jan. 12, 2025 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Capri Holdings Limited (“Capri” or “the Company”) (NYSE: CPRI) and certain of its…
NEW YORK, Jan. 12, 2025 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Capri Holdings Limited (“Capri” or “the Company”) (NYSE: CPRI) and certain of its…
— Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT® (avapritinib) launch and evolving SM prevalence estimates — — Expect to achieve $2 billion in AYVAKIT revenue by 2030 — — BLU-808 demonstrates wide therapeutic window with…
— Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT® (avapritinib) launch and evolving SM prevalence estimates — — Expect to achieve $2 billion in AYVAKIT revenue by 2030 — — BLU-808 demonstrates wide therapeutic window with…
— Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT® (avapritinib) launch and evolving SM prevalence estimates — — Expect to achieve $2 billion in AYVAKIT revenue by 2030 — — BLU-808 demonstrates wide therapeutic window with…
— Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT® (avapritinib) launch and evolving SM prevalence estimates — — Expect to achieve $2 billion in AYVAKIT revenue by 2030 — — BLU-808 demonstrates wide therapeutic window with…